FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2803496106> ?p ?o ?g. }

• W2803496106 abstract "An extrafine formulation of the long-acting muscarinic antagonist, glycopyrronium bromide (GB), has been developed for delivery via the NEXThaler dry powder inhaler (DPI). This study assessed the bronchodilator efficacy and safety of different doses of this formulation in patients with COPD to identify the optimal dose for further development.This was a multicenter, randomized, double-blind, placebo-controlled, incomplete block, three-way crossover study, including three 28-day treatment periods, each separated by a 21-day washout period. Eligible patients had a diagnosis of COPD and post-bronchodilator forced expiratory volume in 1 s (FEV1) 40%-70% predicted. Treatments administered were GB 6.25, 12.5, 25 and 50 μg or matched placebo; all were given twice daily (BID) via DPI, with spirometry assessed on Days 1 and 28 of each treatment period. The primary end point was FEV1 area under the curve from 0 to 12 h (AUC0-12 h) on Day 28.A total of 202 patients were randomized (61% male, mean age 62.6 years), with 178 (88%) completing all the three treatment periods. For the primary end point, all the four GB doses were superior to placebo (p<0.001) with mean differences (95% CI) of 114 (74, 154), 125 (85, 166), 143 (104, 183) and 187 (147, 228) mL for GB 6.25, 12.5, 25 and 50 μg BID, respectively. All four GB doses were also statistically superior to placebo for all secondary efficacy end points, showing clear dose-response relationships for most of the endpoints. Accordingly, GB 25 μg BID met the criteria for the minimally acceptable dose. Adverse events were reported by 15.5, 16.2, 10.9 and 14.3% of patients receiving GB 6.25, 12.5, 25 and 50 μg BID, respectively, and 14.8% receiving placebo.This study supports the selection of GB 25 μg BID as the minimal effective dose for patients with COPD when delivered with this extrafine DPI formulation." @default.
• W2803496106 created "2018-06-01" @default.
• W2803496106 creator A5000903205 @default.
• W2803496106 creator A5011676406 @default.
• W2803496106 creator A5015733174 @default.
• W2803496106 creator A5018090172 @default.
• W2803496106 creator A5044455339 @default.
• W2803496106 date "2018-05-01" @default.
• W2803496106 modified "2023-09-28" @default.
• W2803496106 title "Dose–response of an extrafine dry powder inhaler formulation of glycopyrronium bromide: randomized, double-blind, placebo-controlled, dose-ranging study (GlycoNEXT)" @default.
• W2803496106 cites W1587262260 @default.
• W2803496106 cites W1592776666 @default.
• W2803496106 cites W2056109130 @default.
• W2803496106 cites W2079698487 @default.
• W2803496106 cites W2096872979 @default.
• W2803496106 cites W2109006492 @default.
• W2803496106 cites W2121914298 @default.
• W2803496106 cites W2142096203 @default.
• W2803496106 cites W2167941825 @default.
• W2803496106 cites W2257877995 @default.
• W2803496106 cites W2308810820 @default.
• W2803496106 cites W2344148139 @default.
• W2803496106 cites W2513086234 @default.
• W2803496106 cites W2604743750 @default.
• W2803496106 cites W2727679611 @default.
• W2803496106 cites W2759482297 @default.
• W2803496106 doi "https://doi.org/10.2147/copd.s168493" @default.
• W2803496106 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5973313" @default.
• W2803496106 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29872288" @default.
• W2803496106 hasPublicationYear "2018" @default.
• W2803496106 type Work @default.
• W2803496106 sameAs 2803496106 @default.
• W2803496106 citedByCount "1" @default.
• W2803496106 countsByYear W28034961062021 @default.
• W2803496106 crossrefType "journal-article" @default.
• W2803496106 hasAuthorship W2803496106A5000903205 @default.
• W2803496106 hasAuthorship W2803496106A5011676406 @default.
• W2803496106 hasAuthorship W2803496106A5015733174 @default.
• W2803496106 hasAuthorship W2803496106A5018090172 @default.
• W2803496106 hasAuthorship W2803496106A5044455339 @default.
• W2803496106 hasBestOaLocation W28034961061 @default.
• W2803496106 hasConcept C126322002 @default.
• W2803496106 hasConcept C142724271 @default.
• W2803496106 hasConcept C168563851 @default.
• W2803496106 hasConcept C170493617 @default.
• W2803496106 hasConcept C204787440 @default.
• W2803496106 hasConcept C27081682 @default.
• W2803496106 hasConcept C2775859210 @default.
• W2803496106 hasConcept C2776042228 @default.
• W2803496106 hasConcept C2776312127 @default.
• W2803496106 hasConcept C2776723954 @default.
• W2803496106 hasConcept C2776780178 @default.
• W2803496106 hasConcept C2776885963 @default.
• W2803496106 hasConcept C2776968687 @default.
• W2803496106 hasConcept C2777419714 @default.
• W2803496106 hasConcept C2777714996 @default.
• W2803496106 hasConcept C2780261241 @default.
• W2803496106 hasConcept C2780333948 @default.
• W2803496106 hasConcept C2780667556 @default.
• W2803496106 hasConcept C2781018748 @default.
• W2803496106 hasConcept C2909581452 @default.
• W2803496106 hasConcept C2991744798 @default.
• W2803496106 hasConcept C3018587741 @default.
• W2803496106 hasConcept C42219234 @default.
• W2803496106 hasConcept C71924100 @default.
• W2803496106 hasConcept C87813604 @default.
• W2803496106 hasConceptScore W2803496106C126322002 @default.
• W2803496106 hasConceptScore W2803496106C142724271 @default.
• W2803496106 hasConceptScore W2803496106C168563851 @default.
• W2803496106 hasConceptScore W2803496106C170493617 @default.
• W2803496106 hasConceptScore W2803496106C204787440 @default.
• W2803496106 hasConceptScore W2803496106C27081682 @default.
• W2803496106 hasConceptScore W2803496106C2775859210 @default.
• W2803496106 hasConceptScore W2803496106C2776042228 @default.
• W2803496106 hasConceptScore W2803496106C2776312127 @default.
• W2803496106 hasConceptScore W2803496106C2776723954 @default.
• W2803496106 hasConceptScore W2803496106C2776780178 @default.
• W2803496106 hasConceptScore W2803496106C2776885963 @default.
• W2803496106 hasConceptScore W2803496106C2776968687 @default.
• W2803496106 hasConceptScore W2803496106C2777419714 @default.
• W2803496106 hasConceptScore W2803496106C2777714996 @default.
• W2803496106 hasConceptScore W2803496106C2780261241 @default.
• W2803496106 hasConceptScore W2803496106C2780333948 @default.
• W2803496106 hasConceptScore W2803496106C2780667556 @default.
• W2803496106 hasConceptScore W2803496106C2781018748 @default.
• W2803496106 hasConceptScore W2803496106C2909581452 @default.
• W2803496106 hasConceptScore W2803496106C2991744798 @default.
• W2803496106 hasConceptScore W2803496106C3018587741 @default.
• W2803496106 hasConceptScore W2803496106C42219234 @default.
• W2803496106 hasConceptScore W2803496106C71924100 @default.
• W2803496106 hasConceptScore W2803496106C87813604 @default.
• W2803496106 hasLocation W28034961061 @default.
• W2803496106 hasLocation W28034961062 @default.
• W2803496106 hasLocation W28034961063 @default.
• W2803496106 hasLocation W28034961064 @default.
• W2803496106 hasOpenAccess W2803496106 @default.
• W2803496106 hasPrimaryLocation W28034961061 @default.
• W2803496106 hasRelatedWork W1543718713 @default.
• W2803496106 hasRelatedWork W2002150849 @default.
• W2803496106 hasRelatedWork W2064365837 @default.

• next